Avingtrans (AVG) AI Stock Analysis

• Market Cap: £189.64M
• Dividend Yield: 1.02%
• Average Volume (3M): 61.23K
• Price to Earnings (P/E): 10.7
• Beta (1Y): 0.55
• Revenue Growth: 14.49%
• EPS Growth: 76.33%
• Country: UK
• Employees: 941
• Sector: Industrials
• Sector Strength: 72
• Industry: Industrial - Machinery
• EPS (TTM): 0.15
• Shares Outstanding: 33,269,320
• 10 Day Avg. Volume: 57,336
• 30 Day Avg. Volume: 61,226
• PEG Ratio: 0.25
• Price to Book (P/B): 1.20
• Price to Sales (P/S): 0.87
• P/FCF Ratio: 15.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.3
• Revenue Forecast (FY): £175.02M

• Rating: 70 Outperform
• Price Target: 627.00p ▲(30.63% Upside)
• Action: Upgraded Date: 12/07/25
• Date: Action: Upgraded 12/07/25

Avingtrans' overall stock score is driven by strong financial performance and positive corporate events, which enhance its growth prospects. While the technical analysis suggests a neutral trend, the valuation indicates potential overvaluation. The absence of earnings call data limits insights into management's outlook.

Positive Factors

Balance Sheet Strength

Avingtrans's low debt-to-equity (0.23) indicates durable financial conservatism that supports bidding for capital-intensive contracts, funds capital expenditure and absorbs cyclical downturns. This structural leverage advantage preserves strategic optionality and reduces refinancing risk over months.

Cash Generation

Strong FCF growth and a 0.76 FCF-to-net-income ratio show improving cash conversion that supports reinvestment, working capital and discretionary returns. Sustained cash generation increases resilience for multi‑month project funding and reduces dependency on external financing.

Defensive End Markets

Exposure to nuclear and aerospace, plus through‑life support and spares, gives recurring revenue and structural demand from safety/mission‑critical projects. High technical barriers and long program timelines create durable customer relationships and predictable backlog over several months to years.

Negative Factors

Modest Profitability

A 4.19% net margin is modest for an engineering group and leaves limited buffer against cost inflation or contract overruns. Over a multi‑month horizon, low structural margins constrain retained earnings for growth and increase sensitivity to project execution risks and pricing pressure.

Weak OCF Conversion

An OCF-to-net-income ratio of 0.21 indicates earnings are not yet consistently converted into cash, likely due to project timing and working capital. Persistently low conversion can strain liquidity for project deposits, capex and tendering even if headline FCF improves.

Modest Revenue Growth

Single‑digit revenue growth (~3.36%) suggests limited top‑line momentum and reliance on episodic project wins. Structural growth may be constrained without expanding recurring aftermarket share or larger contract wins, increasing exposure to end‑market cyclicality over months.

Avingtrans Business Overview & Revenue Model

Company Description

Avingtrans plc manufactures and sells engineered components, systems, and services to the energy, medical, and infrastructure industries worldwide. It operates in three segments: Energy-EPM, Energy-PSRE, and Medical-MII. The company designs, manufactures, integrates, and services electric motors and pumps, steam turbines, gas compressors, pressure vessels, blast doors, containers, and skidded systems. It also designs and manufactures equipment for the medical, science and research communities, including products for medical diagnostic equipment; high performance pressure, vacuum vessels, and composite materials for research organizations; and superconducting magnets and helium-free cryogenic systems for use in magnetic resonance imaging and nuclear magnetic resonance. The company was incorporated in 1985 and is based in Chatteris, the United Kingdom.

How the Company Makes Money

Avingtrans generates revenue through multiple streams, primarily by providing component manufacturing and engineering solutions to major customers in the aerospace, defense, and energy sectors. The company earns money by selling high-precision parts and systems, often through long-term contracts with key industry players. Significant partnerships with OEMs (original equipment manufacturers) and other industry leaders enhance its market position and stability of revenue. Additionally, Avingtrans may also benefit from government contracts in the defense sector, which can provide substantial financial support and contribute to its overall earnings.

Avingtrans Financial Statement Overview

Summary

Avingtrans exhibits robust financial performance with consistent revenue growth and improving profitability margins. The balance sheet is strong, characterized by low leverage and effective equity utilization. Cash flow metrics show significant improvement, enhancing the company's financial flexibility. Overall, Avingtrans is well-positioned for future growth, though maintaining margin improvements and cash flow stability will be crucial.

Income Statement

Avingtrans has shown consistent revenue growth over the years, with a notable increase of 3.96% in the latest period. The gross profit margin is healthy at 30.28%, although it has slightly decreased from previous years. The net profit margin has improved to 4.19%, indicating better profitability. EBIT and EBITDA margins have also shown positive trends, reflecting efficient operations.

Balance Sheet

The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.23, suggesting prudent financial management. Return on equity has improved to 5.80%, indicating effective use of equity to generate profits. The equity ratio remains stable, showing a solid capital structure.

Cash Flow

Avingtrans has demonstrated significant improvement in free cash flow, with a growth rate of 61.75%. The operating cash flow to net income ratio is 0.21, indicating moderate cash generation relative to net income. The free cash flow to net income ratio of 0.76 reflects a strong cash conversion cycle.

Breakdown	TTM	May 2024	May 2023	May 2022	May 2021	May 2020
Income Statement
Total Revenue	155.49M	156.41M	136.62M	116.44M	99.08M	98.52M
Gross Profit	48.50M	47.36M	44.04M	36.86M	32.59M	28.38M
EBITDA	16.70M	15.75M	12.54M	13.20M	12.02M	11.03M
Net Income	7.06M	6.56M	3.66M	5.19M	6.48M	3.99M
Balance Sheet
Total Assets	196.40M	192.76M	186.34M	155.41M	154.69M	142.61M
Cash, Cash Equivalents and Short-Term Investments	5.62M	8.56M	12.12M	17.72M	24.29M	30.08M
Total Debt	27.28M	25.47M	23.96M	8.58M	10.96M	9.80M
Total Liabilities	76.54M	77.53M	73.33M	46.96M	48.88M	43.65M
Stockholders Equity	117.28M	113.14M	110.44M	106.04M	103.82M	97.30M
Cash Flow
Free Cash Flow	11.11M	8.80M	-11.06M	985.00K	-1.10M	4.03M
Operating Cash Flow	14.29M	11.61M	1.33M	9.68M	3.88M	6.45M
Investing Cash Flow	-14.67M	-14.29M	-13.58M	-12.52M	-9.35M	24.56M
Financing Cash Flow	-4.05M	-436.00K	6.78M	-3.40M	-371.00K	-5.85M

Avingtrans Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 480.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AVG, the sentiment is Positive. The current price of 480 is below the 20-day moving average (MA) of 575.75, below the 50-day MA of 553.60, and above the 200-day MA of 479.04, indicating a neutral trend. The MACD of 0.67 indicates Positive momentum. The RSI at 51.27 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AVG.

Avingtrans Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVG	70 Outperform	£189.64M	10.69	5.87%	1.02%	14.49%	76.33%
BOY	69 Neutral	£1.23B	9.43	4.10%	3.30%	-6.95%	-52.08%
CGS	65 Neutral	£114.56M	7.63	3.82%	6.69%	-13.30%	-60.03%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
MGAM	62 Neutral	£577.28M	28.89	8.04%	4.87%	-7.30%	-59.71%
MPAC	61 Neutral	£91.72M	-2.99	-17.46%	―	21.17%	-237.25%
ITM	44 Neutral	£385.86M	-8.61	-18.47%	―	57.73%	-67.12%

Avingtrans Corporate Events

Avingtrans Lifts Profit and Dividend as Nuclear and Imaging Units Gain Momentum

Avingtrans reported flat first-half revenue of £78.1m but improved profitability, with gross margin rising to 31.7%, adjusted EBITDA up 10.4% to £9.6m and adjusted profit before tax up 27.1% to £5.7m. Cash generation strengthened, net debt was held at £12.3m despite continued investment in medical imaging and new nuclear technologies, and the interim dividend was lifted to 2.0p per share.

The Advanced Engineering Systems division delivered another strong performance, benefiting from surging global energy demand linked to AI and data centre growth, including a $16m new nuclear contract in South Korea and new UK infrastructure work. The Medical and Industrial Imaging division reduced losses as revenue grew 33%, helped by US FDA 510(k) clearance for Adaptix’s orthopaedic 3D X‑ray system, and with leadership changes and a robust order book, the board signalled confidence in meeting full-year expectations and executing its buy-build-exit strategy to enhance shareholder value.

The most recent analyst rating on (GB:AVG) stock is a Buy with a £650.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.

Avingtrans Issues New Shares Following Employee Option Exercises

Avingtrans has announced that certain non-board employees have exercised 138,900 options under the company’s CSOP scheme, resulting in the issue of an equivalent number of new ordinary shares and an application for their admission to trading on AIM, expected to take effect on 4 February 2026. Following this issuance, Avingtrans will have 33,269,322 ordinary shares in issue with no shares held in treasury, a change that slightly increases the company’s share capital and affects the total voting rights figure that shareholders must use when assessing regulatory disclosure thresholds under the FCA’s transparency rules.

The most recent analyst rating on (GB:AVG) stock is a Buy with a £638.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.

Avingtrans Confirms In-Line First-Half Trading and Eyes Growth from AI, Data Centre and Nuclear Tailwinds

Avingtrans reported that trading for the first six months to 30 November 2025 was in line with management expectations, underpinned by continuing positive momentum across the Group, particularly in businesses exposed to AI and data centre demand and to the revival of nuclear power markets. The company highlighted confidence in meeting market expectations for FY26, citing a buoyant opportunity pipeline and active contract discussions expected to translate into growth from FY27 onwards, while also strengthening its Medical and Industrial Imaging division with the earlier-than-planned appointment of Stuart Gall as CEO and confirming that interim results will be published on 25 February 2026.

The most recent analyst rating on (GB:AVG) stock is a Buy with a £597.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.

Avingtrans Grants Share Options Tied to Inflation-Linked EPS Growth

Avingtrans plc has granted options over 293,000 ordinary shares to non-PDMR employees under its Share Option Plan, with an exercise price of 515.0 pence per share, as part of its long-term incentive arrangements. The options will vest after three years and are contingent on the company’s adjusted earnings per share at least matching the increase in the Retail Prices Index over the vesting period, aligning employee rewards with both company performance and inflation-protected shareholder value.

The most recent analyst rating on (GB:AVG) stock is a Buy with a £539.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.

Avingtrans Names Stuart Gall to Lead Medical and Industrial Imaging Division

Avingtrans has appointed experienced MedTech executive Stuart Gall as Chief Executive Officer of its medical and industrial imaging division, effective 1 January 2026, tasking him with driving the strategic development and commercialisation of portfolio businesses Adaptix, Magnetica and Scientific Magnets. Gall’s track record in scaling medical technology companies from university spin-outs to globally partnered, publicly listed businesses is expected to accelerate market adoption of Avingtrans’ disruptive imaging technologies and support the Group’s efforts to enhance the value of this division for shareholders and strengthen its positioning in high-growth medical and industrial imaging markets.

The most recent analyst rating on (GB:AVG) stock is a Buy with a £539.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.